• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项针对247例非典型肺类癌的多中心研究中的预后因素

Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids.

作者信息

Daddi Niccolò, Schiavon Marco, Filosso Pier Luigi, Cardillo Giuseppe, Ambrogi Marcello Carlo, De Palma Angela, Luzzi Luca, Bandiera Alessandro, Casali Christian, Ruffato Alberto, De Angelis Verena, Andriolo Luigi Gaetano, Guerrera Francesco, Carleo Francesco, Davini Federico, Urbani Moira, Mattioli Sandro, Morandi Uliano, Zannini Piero, Gotti Giuseppe, Loizzi Michele, Puma Francesco, Mussi Alfredo, Ricci Alberto, Oliaro Alberto, Rea Federico

机构信息

Thoracic Surgery Unit, Perugia University School of Medicine, Perugia, Italy.

出版信息

Eur J Cardiothorac Surg. 2014 Apr;45(4):677-86. doi: 10.1093/ejcts/ezt470. Epub 2013 Oct 6.

DOI:10.1093/ejcts/ezt470
PMID:24099733
Abstract

OBJECTIVES

To analyse clinical and biomolecular prognostic factors associated with the surgical approach and the outcome of 247 patients affected by primary atypical carcinoids (ACs) of the lung in a multi-institutional experience.

METHODS

We retrospectively evaluated clinical data and pathological tissue samples collected from 247 patients of 10 Thoracic Surgery Units from different geographical areas of our country. All patients were divided into four groups according to surgical procedure: sub-lobar resections (SURG1), lobar resections (SURG2), tracheobronchoplastic procedures (SURG3) and pneumonectomies (SURG4). Overall survival analysis was performed using the Kaplan-Meier method and log-rank test. Survival was calculated from the date of surgery to the last date of follow-up or death. The parameters evaluated included age, gender, smoking habits, laterality, type of surgery, 7th edition of TNM staging, mitosis Ki-67 (MIB1), multifocal forms, tumourlets, type of lymphadenectomy and neo/adjuvant therapy. For multivariate analysis, a Cox regression model was used with a forward stepwise selection of covariates.

RESULTS

Two hundred and forty-seven patients (124 females and 123 males; range 10-84, median 60 years) underwent surgical resection for AC in the last 30 years as follows: n = 38 patients in SURG1, 181 in SURG2, 15 in SURG3 and 14 in SURG4. A smoking history was present in 136 of 247 (55%) patients. The median follow-up period was 98.7 (range 11.2-369.9) months. The overall survival probability analysis of the AC was 86.7% at 5 years, 72.4% at 10 years, 64.4% at 15 years and 58.1% at 20 years. Neuroendocrine multicentric forms were detected in 12 of 247 patients (4.8%; 1 of 12 pts) during the follow-up (range 11.2-200.4, median 98.7 months) and 33.4% had recurrence of disease. There were no significant differences between gender, tumour location and type of surgery at the multivariate analysis. Age [P < 0.001, hazard ratio (HR) 0.60; confidence interval (CI) 0.32-1.12], smoking habits (P = 0.002; HR 0.43, 95% CI 0.23-0.80) and lymph nodal metastatic involvement (P = 0.008; HR 0.46, 95% CI 0.26-0.82) were all significant at multivariate analysis.

CONCLUSIONS

ACs of the lung are malignant neuroendocrine tumours with a worst outcome in patients over 70 years and in smokers. With the exception of pneumonectomy, the extent of resection does not seem to affect survival and should be accompanied preferably by lymphadenectomy. Pathological staging, along with a mitotic index more than Ki-67 (MIB1), appears to be the most significant prognostic factor at the univariate analysis.

摘要

目的

在一项多机构研究中,分析247例原发性肺非典型类癌(AC)患者的临床和生物分子预后因素,及其与手术方式和预后的关系。

方法

我们回顾性评估了从我国不同地理区域的10个胸外科单位收集的247例患者的临床数据和病理组织样本。所有患者根据手术方式分为四组:肺叶下切除(SURG1)、肺叶切除(SURG2)、气管支气管成形术(SURG3)和全肺切除术(SURG4)。采用Kaplan-Meier法和对数秩检验进行总生存分析。生存时间从手术日期计算至最后一次随访或死亡日期。评估的参数包括年龄、性别、吸烟习惯、病变侧别、手术类型、第7版TNM分期、有丝分裂Ki-67(MIB1)、多灶性形式、微瘤、淋巴结清扫类型以及新辅助/辅助治疗。多因素分析采用Cox回归模型,并对协变量进行向前逐步选择。

结果

在过去30年中,247例患者(124例女性和123例男性;年龄范围10 - 84岁,中位年龄60岁)接受了AC手术切除,具体如下:SURG1组38例,SURG2组181例,SURG3组15例,SURG4组14例。247例患者中有136例(55%)有吸烟史。中位随访期为98.7(范围11.2 - 369.9)个月。AC患者的5年总生存概率分析为86.7%,10年为72.4%,15年为64.4%,20年为58.1%。随访期间(范围11.2 - 200.4,中位98.7个月),247例患者中有12例(占4.8%;12例患者中的1例)检测到神经内分泌多中心形式,33.4%的患者疾病复发。多因素分析显示,性别、肿瘤位置和手术类型之间无显著差异。年龄[P < 0.001,风险比(HR)0.60;置信区间(CI)0.32 - 1.12]、吸烟习惯(P = 0.002;HR 0.43,95% CI 0.23 - 0.80)和淋巴结转移受累情况(P = 0.008;HR 0.46,95% CI 0.26 - 0.82)在多因素分析中均具有显著性。

结论

肺AC是恶性神经内分泌肿瘤,70岁以上患者和吸烟者预后较差。除全肺切除术外,切除范围似乎不影响生存结果,手术最好同时进行淋巴结清扫。单因素分析显示,病理分期以及有丝分裂指数高于Ki-67(MIB1)似乎是最重要的预后因素。

相似文献

1
Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids.一项针对247例非典型肺类癌的多中心研究中的预后因素
Eur J Cardiothorac Surg. 2014 Apr;45(4):677-86. doi: 10.1093/ejcts/ezt470. Epub 2013 Oct 6.
2
Surgical treatment of neuroendocrine tumors of the lung.肺神经内分泌肿瘤的外科治疗
Eur J Cardiothorac Surg. 2004 Oct;26(4):813-7. doi: 10.1016/j.ejcts.2004.05.052.
3
Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung.典型和非典型类癌肿瘤:西班牙肺部神经内分泌肿瘤多中心研究经验分析
Eur J Cardiothorac Surg. 2007 Feb;31(2):192-7. doi: 10.1016/j.ejcts.2006.11.031. Epub 2006 Dec 29.
4
[Surgical treatment of pulmonary carcinoids - ten-year results].[肺类癌的外科治疗——十年结果]
Zentralbl Chir. 2011 Dec;136(6):598-603. doi: 10.1055/s-0031-1271561. Epub 2011 Jul 22.
5
Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.肺大细胞神经内分泌癌的围手术期辅助化疗的临床反应。
Anticancer Drugs. 2010 Jan;21(1):89-93. doi: 10.1097/CAD.0b013e328330fd79.
6
[Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].[保留生育功能手术治疗卵巢恶性生殖细胞肿瘤患者的预后因素分析]
Zhonghua Fu Chan Ke Za Zhi. 2012 Dec;47(12):898-904.
7
[Typical and atypical pulmonary carcinoids--pathologic and clinical analysis of 77 cases].[典型与非典型肺类癌——77例病例的病理及临床分析]
Pneumonol Alergol Pol. 1998;66(5-6):297-303.
8
Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study.局限性和局部进展性非典型肺类癌完全切除后的自然史:法国-意大利回顾性多中心联合研究。
Neuroendocrinology. 2018;106(3):264-273. doi: 10.1159/000480015. Epub 2017 Aug 17.
9
Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience.切除术后肺大细胞神经内分泌癌的新辅助化疗和辅助化疗:单机构经验。
Ann Thorac Surg. 2011 Oct;92(4):1180-6; discussion 1186-7. doi: 10.1016/j.athoracsur.2011.05.027. Epub 2011 Aug 25.
10
Results after surgery in stage-I bronchogenic carcinoma.I期支气管源性癌术后结果。
Thorac Cardiovasc Surg. 1998 Dec;46(6):365-9. doi: 10.1055/s-2007-1010255.

引用本文的文献

1
Surgical management of both stage III and stage IV pulmonary carcinoid tumors confers survival benefit.III期和IV期肺类癌肿瘤的手术治疗均能带来生存获益。
JTCVS Open. 2025 Jun 18;26:218-233. doi: 10.1016/j.xjon.2025.06.005. eCollection 2025 Aug.
2
A Randomized clinical trial evaluating the impact on survival and quality of life of Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).一项评估镥[Lu]依多曲肽与依维莫司对肺和胸腺神经内分泌肿瘤患者生存及生活质量影响的随机临床试验:LEVEL研究(GETNE T-2217)
BMC Cancer. 2025 Apr 4;25(1):613. doi: 10.1186/s12885-025-13941-3.
3
Rare epithelial gastric cancers: a review of the current treatment knowledge.
罕见上皮性胃癌:当前治疗知识综述
Ther Adv Med Oncol. 2025 Jan 24;17:17588359241255628. doi: 10.1177/17588359241255628. eCollection 2025.
4
The presentation pattern and surgical strategies in bronchopulmonary carcinoid tumors: a multicenter experience in a low-income country.支气管肺类癌肿瘤的表现模式及手术策略:低收入国家的多中心经验
Front Surg. 2024 Aug 22;11:1399999. doi: 10.3389/fsurg.2024.1399999. eCollection 2024.
5
Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.评估索凡替尼对比依维莫司或舒尼替尼治疗晚期神经内分泌肿瘤的有效性和安全性:一项使用倾向评分和逆概率处理加权分析的真实世界回顾性队列研究的见解
J Gastrointest Oncol. 2024 Apr 30;15(2):689-709. doi: 10.21037/jgo-24-218. Epub 2024 Apr 29.
6
Lung Carcinoids: A Comprehensive Review for Clinicians.肺类癌:给临床医生的全面综述
Cancers (Basel). 2023 Nov 16;15(22):5440. doi: 10.3390/cancers15225440.
7
Improvement of Lung NET Management through Standardized Care-A Swiss Nationwide Observational Study.通过标准化护理改善肺神经内分泌肿瘤管理——一项瑞士全国性观察性研究
Cancers (Basel). 2023 Apr 13;15(8):2270. doi: 10.3390/cancers15082270.
8
Prognostic factors for pulmonary carcinoid with positive lymph node after surgical resection: a SEER database study.肺类癌术后淋巴结阳性的预后因素:一项 SEER 数据库研究。
Gen Thorac Cardiovasc Surg. 2023 Jul;71(7):409-417. doi: 10.1007/s11748-023-01910-1. Epub 2023 Jan 27.
9
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review.高分化神经内分泌肿瘤(NET)G1、G2和G3的化疗:一项叙述性综述
J Clin Med. 2023 Jan 16;12(2):717. doi: 10.3390/jcm12020717.
10
Surgical Principles in the Management of Lung Neuroendocrine Tumors: Open Questions and Controversial Technical Issues.肺神经内分泌肿瘤的外科治疗原则:未解决的问题和有争议的技术问题。
Curr Treat Options Oncol. 2022 Dec;23(12):1645-1663. doi: 10.1007/s11864-022-01026-3. Epub 2022 Oct 21.